{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:01:47Z","timestamp":1793037707205,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1136\/annrheumdis-2016-210233","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T23:41:27Z","timestamp":1480462887000},"page":"878-881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series"],"prefix":"10.1016","volume":"76","author":[{"given":"G","family":"Varkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Thevissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"De Brabanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Czul-gurdian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Cypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"De Kock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Carron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hindryckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Vanneuville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schoenaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Claerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Elewaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2016-210233_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2016-210233_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2016-210233_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"10.1136\/annrheumdis-2016-210233_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.151.2.717","article-title":"Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism","volume":"151","author":"Schweighoffer","year":"1993","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2016-210233_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.181.1.137","article-title":"Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms","volume":"181","author":"Salmi","year":"1995","journal-title":"J Exp Med"},{"key":"10.1136\/annrheumdis-2016-210233_bib6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1172\/JCI119389","article-title":"Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion","volume":"99","author":"Salmi","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1136\/annrheumdis-2016-210233_bib7","first-page":"1932","article-title":"Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis","volume":"25","author":"Elewaut","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210233_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00054725-199805000-00026","article-title":"Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD","volume":"4","author":"Salmi","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/annrheumdis-2016-210233_bib9","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.166.7.4650","article-title":"Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules","volume":"166","author":"Salmi","year":"2001","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2016-210233_bib10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1136\/annrheumdis-2016-210233_bib11","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut Published Online First: 18 Feb 2016. doi: 10.1136\/gutjnl-2015-311079 doi:10.1136\/gutjnl-2015-311079","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"10.1136\/annrheumdis-2016-210233_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1136\/annrheumdis-2016-210233_bib13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2016-210233_bib14","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210233_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1136\/annrheumdis-2016-210233_bib16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2016-210233_bib17","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.4049\/jimmunol.149.4.1424","article-title":"Alpha 4\/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes","volume":"149","author":"Morales-Ducret","year":"1992","journal-title":"J Immunol"},{"key":"10.1136\/annrheumdis-2016-210233_bib18","first-page":"2860","article-title":"Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association","volume":"27","author":"de Vlam","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2016-210233_bib19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724027924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2016-210233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:34:19Z","timestamp":1736044459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724027924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0003496724027924"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210233","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http:\/\/www.bmj.com\/company\/products-services\/rights-and-licensing. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}